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Abstract
Background: A recent study reported that gene expression profiles from peripheral blood samples of healthy
subjects prior to viral inoculation were indistinguishable from profiles of subjects who received viral challenge but
remained asymptomatic and uninfected. If true, this implies that the host immune response does not have a
molecular signature. Given the high sensitivity of microarray technology, we were intrigued by this result and
hypothesize that it was an artifact of data analysis.
Findings: Using acute respiratory viral challenge microarray data, we developed a molecular signature that for the
first time allowed for an accurate differentiation between uninfected subjects prior to viral inoculation and subjects
who remained asymptomatic after the viral challenge.
Conclusions: Our findings suggest that molecular signatures can be used to characterize immune responses to
viruses and may improve our understanding of susceptibility to viral infection with possible implications for vaccine
development.
Background
Acute respiratory viral infections cause significant mor-
bidity and mortality in the United States and worldwide.
Currently clinicians do not have practical means to
make a timely and accurate diagnosis of acute viral
respiratory infections and often resort to unnecessary
antibiotic treatment, which increases healthcare costs
and facilitates development of antibiotic resistance.
Recently a novel approach was proposed for the diagno-
sis of acute respiratory infections based on microarray
gene expression profiles from peripheral blood samples
from human subjects [1]. Using human viral challenge
studies with live human rhinovirus (HRV), respiratory
syncytial virus (RSV), and influenza A, Zaas et al. devel-
oped an “acute respiratory viral response” 30-gene pan-
viral signature that accurately identified symptomatic
patients with viral infection. The same study also
reported that gene expression profiles of subjects prior
to viral inoculation (at baseline) were indistinguishable
from profiles of subjects who received viral challenge
but remained asymptomatic and uninfected. Given the
high sensitivity of microarray technology, we were intri-
gued by the latter result and hypothesize that it was an
artifact of data analysis. Since the gene expression data-
set of Zaas et al. was deposited in the Gene Expression
Omnibus, we were able to verify our hypothesis and dis-
cover significant differences between these two groups
of samples. We demonstrate this by developing a mole-
cular signature that discriminates with high accuracy
between uninfected subjects at baseline (prior to viral
inoculation) and asymptomatic subjects at the time cor-
relating to peak symptoms in the symptomatic group.
This finding has important implications for a better
understanding of the complex human immune response
to viral antigens. Genes that are differentially expressed
in the two groups may provide important clues about
decreased susceptibility to viral challenge, which could
result in more effective vaccine development or novel
therapeutic strategies.
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To arrive at our findings, we reanalyzed the gene
expression data of Zaas et al. that contains measure-
ments of 22,277 oligonucleotide probes for 56 blood
samples from uninfected subjects (measured at baseline,
prior to inoculation) and 30 blood samples from sub-
jects who received viral challenge but remained asymp-
tomatic (measured at corresponding peak symptoms
time specific for each virus). We used an improved
data-analytic protocol that avoids selection of redundant
and biologically irrelevant genes and at the same time
maximizes predictive accuracy of the signature [2]. This
protocol has recently allowed us to develop a highly
accurate and compact molecular signature for differen-
tiation between uninfected subjects and those with acute
respiratory viral infections. This signature had high
reproducibility as evidenced by its nearly perfect accu-
racy in the independent data of Ramilo et al. [3], and
was comprised of genes that are involved in the host
immune response [2].
Our data-analytic protocol first involved selection of
genes by GLL-PC, a supervised multivariate biomarker
discovery method that provably discovers genes in the
local pathway around the response variable of interest
[4,5]; additional details about GLL-PC are provided in
[Additional file 1]. Next, Support Vector Machine
(SVM) classifiers with linear kernel and penalty hyper-
parameter C = 100 were fitted on the selected genes [6].
In order to obtain an unbiased estimate of predictive
accuracy that will hold in applications of this molecular
signature on future subjects, gene selection and SVM
classifier training were performed by stratified 10-fold
cross-validation repeated 100 times for different splits of
subject into 10 folds [2,7]. Finally, we ensured signature
reproducibility and assessed its statistical significance by
using a permutation test with significance level a =0 . 0 5
and 10,000 permutations [8].
Results and Discussion
The data-analytic protocol described above yields an
unbiased estimate of predictive accuracy = 0.85 area
under ROC curve (AUC); 95% confidence interval [0.76;
0.94] AUC. On average GLL-PC selected 7 genes
depending on the training set of cross-validation. Genes
selected by GLL-PC in more than 20% of the training
sets are listed in Table 1. Genes that were selected in a
smaller fraction of training sets may be artifacts of small
sample size. Next, GLL-PC and SVM were applied on
the entire set of samples, resulting in a 6-gene signature
comprised of genes EIF2S1, ZNF91, RBM3, ATP5S,
TPPP3, GPR97.N o t et h a ta l lt h e s es i xg e n e sw e r ea l s o
among the top seven most frequently selected by GLL-
PC during cross-validation (Table 1), which demon-
strates the stability of this gene set despite the inherent
heterogeneity of gene expression across subjects.
Of the eight genes shown in Table 1, four are known
to be involved in the host immune response. EIF2S1
encodes the alpha subunit of the translation initiation
factor eIF2 complex (eIF2a), which initiates protein
synthesis. This protein appears to be crucial for the sur-
vival of virally infected cells [9]. The increase of expres-
sion of EIF2S1 that is observed in the data could mean
that host protein synthesis is turned on as response to
viral exposure. On the other hand, many viruses, includ-
ing influenza A viruses, have developed mechanisms
favoring the translation of viral over cellular mRNAs
leading to a switch from cellular to viral protein synth-
esis, while inhibiting the cell-encoded antiviral pathways
[10]. RBM3 encodes a protein that is a member of the
heterogeneous nuclear ribonucleoproteins (hnRNPs)
that appears to enhance global protein synthesis [11]
but also has a role in viral transcription and replication
[12]. The ZNF91 gene family is a subset of the Krüppel-
associated box (KRAB)-containing group of zinc finger
genes. Zinc-finger proteins containing the KRAB





Gene name Frequency of selection by GLL-PC during cross-
validation
201143_s_at EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa 99%
218876_at TPPP3 tubulin polymerization-promoting protein family member 3 95%
206059_at ZNF91 zinc finger protein 91 94%
208319_s_at RBM3 RNA binding motif (RNP1, RRM) protein 3 74%
220404_at GPR97 G protein-coupled receptor 97 67%
202124_s_at TRAK2 trafficking protein, kinesin binding 2 58%
213995_at ATP5S ATP synthase, H+ transporting, mitochondrial F0 complex, subunit s
(factor B)
32%
208650_s_at CD24 CD24 molecule 20%
Genes that were also selected by GLL-PC on the entire set of samples are shown with bold.
Statnikov et al. BMC Research Notes 2010, 3:264
http://www.biomedcentral.com/1756-0500/3/264
Page 2 of 4domain are transcriptional regulators that have been
associated with suppression of viral proliferation [13].
The related transcriptional factor OTK18 has been
shown to be induced by and to suppress HIV-1 infec-
tion in mononuclear cells [14]. Finally, CD24 is involved
in the CD24-Siglec G pathway that protects the host
against a fatal reaction to pathological cell death and
discriminates danger- versus pathogen-associated mole-
cular patterns [15].
To the best of our knowledge, the remaining 4 genes
from Table 1 (TPPP3, GPR97, ATP5S, TRAK2)h a v en o t
yet been specifically associated with host immune
responses, however this does not rule them out as novel
pharmaceutical targets. Some of these genes are
involved in normal cellular function and for some there
is evidence of their association with host immune
responses: TPPP3 encodes members of the tubulin
family of proteins, and one study has shown an increase
of tubulin in influenza infection [16]. GPR97 encodes a
member of G protein-coupled receptors that bind che-
mokines on the surface of immune cells. Chemokine
signaling is critical for effective antiviral immune
response activation. ATP5S encodes a subunit of mito-
chondrial ATP synthase, and it has been suggested that
an increase in mitochondrial activity plays a relevant
role in viral replication [17]. TRAK2 encodes a traffick-
ing factor that facilitates expression of potassium chan-
nels to the cell surface [18].
In further analysis, we identify a likely reason that pre-
cluded Zaas et al. from detecting a difference between
uninfected subjects at baseline and asymptomatic sub-
jects at corresponding peak time. The study of Zaas et
al. used 30 genes from the “acute respiratory viral
response” signature (that was designed for differentia-
tion of symptomatic subjects from uninfected indivi-
duals) to perform a different classification task. It is
therefore not surprising that even though these 30 genes
were predictive for diagnosis of symptomatic subjects
from uninfected individuals, they were not predictive for
differentiating uninfected subjects at baseline from
asymptomatic subjects at the time corresponding to
peak symptoms in the symptomatic group. We have ver-
ified this assertion by running the original data analysis
software of Zaas et al. that resulted in random predic-
tive accuracy (0.50 AUC) when using 30 genes from the
“acute respiratory viral response” s i g n a t u r ea n dan o n -
trivial predictive accuracy (0.66 AUC) when using genes
selected specifically for the classification task of interest.
The remainder of the discrepancy between performance
of the protocol of Zaas et al. and one used in the pre-
sent study is due to the choice of methods for gene
selection, classification, and accuracy estimation (cross-
validation). If we substitute sparse probit regression with
SVMs in the analysis protocol of Zaas et al.,t h e
predictive accuracy increases to 0.75 AUC. If we also
substitute factor analysis-based gene selection with
GLL-PC and use repeated 10-fold cross-validation, we
obtain the result identical to our analysis, i.e. 0.85 AUC.
Conclusions
In summary, upon reanalysis, the data provided in the
study by Zaas et al. [1] demonstrate that there is a dif-
ference between gene expression profiles of the unin-
fected subjects prior to viral exposure and the
asymptomatic subjects after the exposure. This observa-
tion is important for understanding host immune
response and warrants validation in independent gene
expression data and/or with RT-qPCR. A more detailed
understanding of molecular factors that enable some
exposed subjects to avoid infection or remain asympto-
matic after the exposure while others demonstrate clini-
cal illness could provide targets for development of
more effective vaccines and antiviral treatments. More
studies should be undertaken to better characterize the
gene expression changes in specific viral infections and
patient populations.
Additional material
Additional file 1: GLL-PC and one of its instantiations - Semi-
interleaved HITON-PC. This file contains a description of the supervised
biomarker discovery framework GLL-PC and one of its instantiations,
termed Semi-interleaved HITON-PC, that was used in this work.
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